QQ客服 官方微博 反馈留言

	Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial
	Li, Li; Zhuang, Qingqing; Cao, Zeyi; Yin, Rutie; Zhu, Yaping; Zhu, Lirong; Xie, Xing; Zhang, Youzhong; Li, Li; Wu, Qiang
刊名	ONCOLOGY LETTERS
	2018
卷号	15期号:3页码:3646-3652
关键词	epithelial ovarian cancer nedaplatin carboplatin paclitaxel chemotherapy
DOI	10.3892/ol.2018.7761
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4581585
专题	山东大学
作者单位	1.Guangxi Med Univ, Canc Hosp, Dept Gynecol, Nanning 530021, Guangxi, Peoples R China. 2.First Peoples Hosp Jining, Dept Gy
推荐引用方式 GB/T 7714	Li, Li,Zhuang, Qingqing,Cao, Zeyi,et al. Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial[J]. ONCOLOGY LETTERS,2018,15(3):3646-3652.
APA	Li, Li.,Zhuang, Qingqing.,Cao, Zeyi.,Yin, Rutie.,Zhu, Yaping.,...&Zheng, J 更多.(2018).Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial.ONCOLOGY LETTERS,15(3),3646-3652.
MLA	Li, Li,et al."Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial".ONCOLOGY LETTERS 15.3(2018):3646-3652.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。